Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma

Fig. 2

CAR-T cell expansion, and change of inflammatory indicators post infusion. a The CAR transgene copies of mononuclear cells from peripheral blood for patient 1 (in red), and from peripheral blood (in blue) and pleural effusion (in green) for patient 2 was detected by digital PCR at serial points post infusion. The Tmax of CAR transgene in peripheral blood for the two patients was 13 and 12 days, respectively. The Cmax of CAR transgene in peripheral blood was 39,670 and 9707 copies/μg gDNA, respectively. b The quantity of CAR+ and CD3+ T cells were verified by flow cytometry. The change of CAR+/CD3+ T cells at serial points post infusion was in accordance with CAR transgene copies. The peak of CAR+ cell proportion occurred at around two weeks. c A high proportion (95.08%) of CAR-T cell infiltration was detected by flow cytometry in the pleural effusion of patient 2. The serum levels of interluekin-6 d, hypersensitive C reactive protein (e), and ferritin (f) at serial points post infusion was recorded. All these three factors rose to the peak at around day 7 in patient 1 and day 14 in patient 2, and then decreased, which was also in accordance with the change of CAR transgene copies. Abbreviations: Cmax: the peak value of CAR transgene copies; hsCRP, hypersensitive C reactive protein PCR, polymerase chain reaction; Tmax, the time of CAR transgene copies to reach the peak

Back to article page